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Research conducted over the past 20 years have helped us unravel not only the hidden
structural and functional subtleties of human C1q, but also has catapulted the molecule
from amere recognition unit of the classical pathway to awell-recognizedmolecular sensor
of damage-modiﬁed self or non-self antigens. Thus, C1q is involved in a rapidly expanding
list of pathological disorders – including autoimmunity, trophoblast migration, preeclamp-
sia, and cancer.The results of two recent reports are provided to underscore the critical role
C1q plays in health and disease. First is the observation by Singh et al. (2011) showing that
pregnant C1q−/− mice recapitulate the key features of human preeclampsia that correlate
with increased fetal death. Treatment of the C1q−/− mice with pravastatin restored tro-
phoblast invasiveness, placental blood ﬂow, and angiogenic balance and, thus, prevented
the onset of preeclampsia. Second is the report by Hong et al. (2009) which showed
that C1q can induce apoptosis of prostate cancer cells by activating the tumor suppressor
moleculeWW-domain containing oxydoreductase (WWOX orWOX1) and destabilizing cell
adhesion. Downregulation of C1q on the other hand, enhanced prostate hyperplasia and
cancer formation due to failure ofWOX1 activation. C1q belongs to a family of structurally
and functionally related TNF-α-like family of proteins that may have arisen from a com-
mon ancestral gene. Therefore C1q not only shares the diverse functions with the tumor
necrosis factor family of proteins, but also explains why C1q has retained some of its
ancestral “cytokine-like” activities. This review is intended to highlight some of the struc-
tural and functional aspects of C1q by underscoring the growing list of its non-traditional
functions.
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INTRODUCTION
The ﬁrst component of complement, C1, is a multimolecular
complex comprising of C1q and a Ca2+-dependent tetramer,
C1r2–C1s2. The role of C1q within this complex is to serve as a
recognition signal – a signal that is readily translated into a highly
speciﬁc and orderly intramolecular rearrangement resulting in a
sequential proteolytic activation – ﬁrst of C1r and then of C1s –
thereby triggering activation of the classical pathway (Cooper,
1985; Schumaker et al., 1987; Arlaud et al., 2001). However, the
role of C1q is not restricted to recognition of immune complexes
or other molecules that activate the classical pathway. Evidence
accumulated to date clearly demonstrates that C1q is a key player
in a rapidly expanding list of pathophysiological conditions which
include: trophoblast invasion and placental development (Agosti-
nis et al., 2010), onset of preeclampsia (Singh et al., 2011), regula-
tion of autoimmune diseases such systemic lupus erythematosus
(SLE; Walport et al., 1998) and activation of the tumor suppressor
molecule WW-domain containing oxydoreductase, which plays a
Abbreviations: cC1q, the collagen domain of C1q; cC1qR, receptor for cC1q; CRT
(identical to cC1qR), calreticulin; gC1q, the globular heads of C1q; gC1qR, recep-
tor for gC1q; ghA, ghB, and ghC, globular heads of the A, B, and C chains of C1q
respectively.
critical role in the pathogenesis of prostate cancer (Hong et al.,
2009).
Unlike most of the complement proteins, which by and large
are synthesized in the liver, C1q is synthesized extrahepatically
by a wide range of cell types including monocytes/macrophages
(Bensa et al., 1983; Loos, 1983; Tenner and Volkin, 1986; Kolosov
et al., 1996; Armbrust et al., 1997), epithelial cells (Colten, 1976)
mesenchymal cells (Morris et al., 1978), dendritic cells (Vegh
et al., 2003; Castellano et al., 2004a), trophoblasts (Bulla et al.,
2008; Agostinis et al., 2010), microglial cells (Lynch et al., 2004;
Farber et al., 2009), ﬁbroblasts (Reid and Solomon, 1977; Skok
et al., 1981; Gulati et al., 1993), and endothelial cells (Bulla et al.,
2008; Bossi et al., 2011). The synthesized molecule in turn, is
either transiently expressed as a cell membrane associated mol-
ecular ligand (mC1q; Loos, 1983), or secreted into the pericellular
milieu where it can modulate cell-speciﬁc biological responses
in a manner that involves an autocrine and/or paracrine signal-
ing through cell surface receptors and their signaling partners
(Menzies et al., 2008). The diversity of immunological func-
tions mediated by C1q could perhaps be explained by having
a unique structural feature: a collagen-like domain (cC1q) and
a globular heads domain (gC1q) present in the same protein.
This paper will shed some light into the evolution and structural
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basis of C1q function and highlight some of its emerging novel
functions.
STRUCTURE OF HUMAN C1q
Human C1q (460 kDa) is a collagen-like, structurally com-
plex, hexameric glycoprotein, which associates with the Ca2+-
dependent C1r2–C1s2 tetramer (360 kDa) to form the pentameric
C1, the ﬁrst component of the serum complement system (Cal-
cott and Müller-Eberhard, 1972; Reid and Thompson, 1983; Reid,
1989). It is composed of six globular “heads” linked via six
collagen-like “stalks” to a ﬁbril-like central region (Shelton et al.,
1972; Svehag et al., 1972; Knobel et al., 1975; Brodsky-Doyle et al.,
1976; Sellar et al., 1991). The C1q molecule (Figure 1), consists
of 3 remarkably similar but distinct polypeptide chains, A, B, and
C, each of which occurs 6 times in the molecule to give rise to a
total of 18 chains (6A, 6B, 6C; Reid, 1989). The three chains are
the product of three distinct genes, which are aligned 5′ ⇒ 3′, in
the same orientation, in the order A–C–B on a 24-kb stretch of
DNA on chromosome 1p (Reid, 1985; Sellar et al., 1991). Each
polypeptide chain (A= 28 kDa, B= 25 kDa, C= 24 kDa) consists
of 81 amino acid-long collagen-like N -terminal “stalk” and a C-
terminal, globular “head” of 136 amino acids (Reid, 1989). The
chains are arranged to form 6 triple helical strands, three pep-
tide chains, A, B, and C, forming one strand (Figure 1). In each
strand, the triple helix is formed between theN -terminal collagen-
like sequences of the three chains while the globular “head” is
formed from the C-terminal portion of these chains (Sellar et al.,
1991; Kishore and Reid, 1999). Chains A and B are disulﬁde-
linkedwithin a given strand through formationof disulﬁde bridges
between the half-cysteine residues located at A-4 and B-4, whereas
the C chain forms a disulﬁde bond with the C chain of the next
strand through cysteine residues found at position C-4 (Reid,
1989). Thus, the two disulﬁde-linked strands form a doublet, and
three doublets are linked by non-covalent forces to give C1q its
signature electron microscopic structure resembling a bouquet of
tulips (Shelton et al., 1972; Brodsky-Doyle et al., 1976; Figure 1).
Approximately 8% (w/w) of human C1q is carbohydrate, which
is in the form of glucosylgalactosyl disaccharide units linked to
hydroxylysine residues in the cC1q domain, and six asparagine-
linked sugar chains located in the gC1q domain (Yonemasu et al.,
1971; Calcott and Müller-Eberhard, 1972; Reid et al., 1972). The
two types of sugars in turn account for approximately 69 and
31% of the total carbohydrate respectively (Mizuochi et al., 1979;
Shinkai and Yonemasu, 1979; Reid, 1989).
From a structure–function point of view, the C1q molecule
contains two very well deﬁned major functional domains through
which it enters into a wide range of molecular interactions. These
domains are known as the collagen-like domain (cC1q), and the
globular “heads”domain (gC1q).Of these, the gC1qdomain,which
recognizes a wide range of molecular patterns including modiﬁed-
self and non-self antigens, is considered to be key to the versatility
of C1q function (Gaboriaud et al., 2009). The two domains of C1q
can be puriﬁed separately after the intact C1q molecule is ﬁrst sub-
jected to either peptic digestion at pH4.45,or collagenase digestion
FIGURE 1 | Schematic model of the subunit structure and assembly of
intact of C1q.Three similar chains – A, B, and C – are assembled to form
disulﬁde-linked A–B and C–C dimers. One strand of the molecule consists of
an A–B dimer non-covalently linked to a C chain forming (A–B–C). The C chain
of one strand is then disulﬁde-linked to the C chain of a neighboring strand to
give an A–B C–C B–A doublet and three such doublets are linked by
non-covalent forces giving C1q its ﬁnal signature “bouquet-like” structure. The
length of each chain as well as the length of the gC1q and cC1q domains (for
brevity, g- or c-domain) is given in parenthesis. (The ﬁgure was adapted from
Reid, 1989).
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at near neutral pH 7.4 (Knobel et al., 1974). The respective puriﬁed
heterotrimeric domains can then be used in functional studies,
although the afﬁnity of the individual trimeric gC1q domain is
likely to be several-fold less than that of the intact C1q because of
the multivalency of the latter (Tacnet et al., 2008). Evidence accu-
mulated to date convincingly shows that the two domains of C1q
participate in amultiplicity of immunological functions by serving
as a binding sites for a long list of pathogen-associated molecular
patterns (PAMPs) as well as danger associated molecular patterns
(DAMPs). These include viral proteins such as gp41 (Ebenbich-
ler et al., 1991), acute phase proteins such as C-reactive protein
(Jiang et al., 1991; Gewurz et al., 1993), bacterial and mitochondr-
ial membranes (Gewurz et al., 1993), DNA (Jiang et al., 1991), as
well as β-amyloid peptide (Jiang et al., 1994; Tacnet-Delorme et al.,
2001). The gC1q domain has a heterotrimeric structure composed
of the C-terminal halves of each of the three chains A, B, and C,
and each of these heterotrimeric structures are postulated to func-
tion independently (Kishore and Reid, 1999, 2000). Because of the
availability of recombinant forms of each of the globular heads
(gh) or modules, it has now been possible to purify the individual
modules (ghA, ghB, and ghC) as recombinant proteins and study
their individual roles in ligand binding and biological function
(Kishore et al., 2003; Ghai et al., 2007). Indeed, mutational studies
using ghA, ghB, and ghC modules have identiﬁed the gh residues
involved in recognition of IgG and IgM (Kojouharova et al., 2004;
Gadjeva et al., 2008). In addition to recognition of self andnon-self
antigens, C1q can enter into a vast array of interactions by binding
to cell surface molecules either via its cC1q or gC1q domain. C1q
receptors mediate a plethora of immunologic functions including
phagocytosis, and clearance of apoptotic cells (Bobak et al., 1987;
Nauta et al., 2002; Païdassi et al., 2011).
Although the list of cell surface or cell associated molecules rec-
ognized by C1q is increasing, there are at least two well character-
ized and ubiquitously distributed cell surface molecules – known
respectively as cC1qR and gC1qR– that recognize the two domains
of C1q (Ghebrehiwet and Peerschke, 2004a). Although each of
these molecules lacks a consensus sequence motif for a traditional
transmembrane segment, the lack of direct conduit to intracel-
lular signaling elements is circumvented by the formation of a
docking/signaling complex with transmembrane proteins. This
partnership in turn is dictated by the speciﬁc biological response to
be induced (Ghebrehiwet et al., 2001; Ghebrehiwet and Peerschke,
2004a). Each of these receptors is a multiligand binding protein
capable of inducing a wide range of cellular functions (Ghebre-
hiwet and Peerschke, 2004a). More importantly, binding of C1q
to cell surfaces via either receptor induces a plethora of biological
functions that play a critical role in innate and adaptive immunity,
inﬂammation, infection, and cancer (Ghebrehiwet et al., 2001).
THE C1q FAMILY OF PROTEINS
From data available to date, it has become clear that the unusual
feature of having a collagen-like and globular region in the same
protein is not unique to C1q. Instead, the data show that C1q
belongs to a long list of oligomeric proteins that are struc-
turally and functionally similar. These proteins, whose mem-
bers include: mannan-binding lectin (MBL), lung surfactant pro-
tein A (SP-A), SP-D, collectin-43 (CL-43), collectin-46 (CL-46),
and bovine conglutinin (Malhotra et al., 1992) are collectively
known as collectins (col lagen containing lectins) by virtue of
having collagen-like sequences contiguous with non-collagen-like
stretches (Hoppe and Reid, 1994). Collectins are calcium depen-
dent molecules and belong to a group III of the family of lectins
containing C-type carbohydrate recognition domains (CRD; Lu
et al., 1993; Hakansson and Reid, 2000). Their genes characteris-
tically contain a small exon encoding a 36 amino acid-long neck
region,which links the collagendomainwith theCRD.TheCRD in
turn, is responsible for recognition of glycoconjugates containing
mannose and fucose on microorganisms but not on self-proteins,
resulting in enhanced clearance of pathogenic microorganisms
(Hakansson and Reid, 2000). Unlike the collectins however, C1q
doesnot possess a consensusdomain forCRD,but it shares another
common feature with the collectins in that it possesses galactose–
glucose disaccharides attached to the collagenous regions of each
protein (Mizuochi et al., 1979; Reid, 1979; Shinkai and Yone-
masu, 1979). Despite lacking a CRD domain however, recent data
suggest that C1q also has lectin-like activity suggesting that carbo-
hydrates – especially those on pathogens and apoptotic cells – may
provide additional binding targets where the binding of C1q is
critical for removal of self waste (Païdassi et al., 2008).
In addition to the collectins, several other molecules, which are
structurally similar to C1q, have also been described. One of these
is, adipocyte complement-related protein of 30 kDa (ACRP30) or
adiponectin (Scherer et al., 1995; Hu et al., 1996; Berg et al., 2001;
Wong et al., 2004). ACRP30 or adiponectin, is secreted exclu-
sively from fat cells and implicated in energy homeostasis and
obesity as well as enhancement of hepatic insulin action (Berg
et al., 2001; Wong et al., 2004). It is a protein of 247 amino
acids consisting of an N -terminal collagen-like domain and a C-
terminal globular domain (Scherer et al., 1995; Berg et al., 2001).
The globular domain shares a signiﬁcant homology to the globular
domains of type VIII and X collagens as well as subunits of C1q.
More intriguing however is the fact that the crystal structure of
a homotrimeric fragment from ACRP30 revealed an unexpected
homology to the tumor necrosis factor (TNF) family of proteins.
Because of identical folding topologies, key residue conservations,
and similarity of trimer interfaces and intron positions, these stud-
ies have ﬁrmly established an evolutionary link between theTNF-α
and the C1q family of proteins suggesting that TNF arose by
divergence from an ancestral recognition molecule of the innate
immune system (Shapiro and Scherer, 1998). The evolutionary
connection between C1q-like proteins and TNF-α, which control
many aspects of inﬂammation, adaptive immunity, apoptosis, and
energy homeostasis, not only sheds insight into the shared diverse
functions of this family of proteins (Shapiro and Scherer, 1998),
but also explains why C1q has retained some of its “cytokine-like”
activities. Structurally, the C1q/TNF family of proteins contains
the same compact “jellyroll” β fold, usually organized as trimers
butwithdiverse functions ranging fromcytokine activity (TNF-α),
regulation of metabolism (ACRP30), connective tissue organiza-
tion (collagen type VIII and X), cellular activation (CD40L), and
innate immunity (C1q; Kishore et al., 2002, 2004; Gaboriaud et al.,
2007). More recently, the crystal structure of the gC1q domain of
C1q was solved and the structure reveals a compact, almost spher-
ical heterotrimeric assembly held together mainly by non-polar
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interactions, with a Ca2+ ion bond at the top of the molecule
(Gaboriaud et al., 2009). More importantly, the structural stud-
ies revealed that the heterotrimeric assembly of the gC1q domain
appears to have unique features that allow its versatility (Gabori-
aud et al., 2009). Other molecules in which the “gC1q domains”
are found at the C-terminal end include: precerebellin (Kavety
et al., 1994), multimerin (Hayward et al., 1995), and types VIII
and X collagens (Bogin et al., 2002). Therefore, despite its similar-
ities with the collectins, the structural folds of the gC1q domain,
which are more similar to the TNF than to the CRD region of the
collectins – make C1q more related to the TNF family of proteins
(Kishore et al., 2004).
The signiﬁcance of a particular human protein is sometimes
underscored by the fact that pathogenic microorganisms speciﬁ-
cally mimic its functional domain or antigenic determinant for the
purpose of immune evasion and thus enhance their survival. For
example, the three-dimensional structure of themajor surface pro-
tein of Bacillus anthracis spore surface protein, bacillus collagen-
like protein of anthracis (BclA) reveals remarkable similarity to
C1q – although there is only low sequence identity between the
two proteins (Sylvestre et al., 2002; Rety et al., 2005). Furthermore,
both BclA and C1q have been shown to bind to lung alveolar sur-
factant component-SP-C, suggesting that both recognize common
targets in the alveolar component (Rety et al., 2005). This molecu-
lar mimicry in turn, underscores not only the functional relevance
of the gC1q domain, but also pathogenic microorganisms mimic
this signature domain in order to get access into host cells. The
exosporiumof B. cereus,which belongs to the same genus of spore-
forming aerobic bacteria as B. anthracis, contains a binding site for
gC1qR.Although the nature of theB. cereus molecule has not been
as yet identiﬁed, the fact that it recognizes gC1qR on cells for the
initial spore attachment and entry suggests that this molecule may
also contain a gC1q-like domain (Ghebrehiwet et al., 2009).
THE DIVERSE BIOLOGICAL FUNCTIONS OF C1q
Although for many years, the traditionally accepted role of C1q is
the recognition of immune complexes and activation of the clas-
sical pathway, there is an ever-growing body of evidence, which
suggests that C1q is a major sensor of DAMPs and PAMPS and
plays a critical role in inﬂammation as well as innate and adap-
tive immunity (Figure 2) (Kojouharova et al., 2003; Sontheimer
et al., 2005; Ghai et al., 2007; Gadjeva et al., 2008; Païdassi et al.,
2008; Hosszu et al., 2010). In addition, C1q induces a plethora
of immunologic functions by interaction with distinct cell sur-
face molecules, which recognize either, its gC1q or cC1q domain
(Ghebrehiwet and Peerschke, 2004a). These cell surface molecules
include cC1qR or calreticulin (CR), gC1qR (Malhotra et al., 1992;
Ghebrehiwet and Peerschke, 2004a) CD93 (Nepomuceno et al.,
1997; Steinberger et al., 2002), as well as other associated adapter
molecules such as CD91 (Ogden et al., 2001; Gardai et al., 2003),
CD44,DC-SIGN, and β1 integrin (Feng et al., 2002; Menzies et al.,
2008). Interaction of C1q with cell surface molecules, induces a
wide range of biological responses including stimulation of leuko-
cyte oxidative response (Tenner and Cooper, 1982), phagocytosis
(Bobak et al., 1987), suppression of B and T cell proliferation
(Ghebrehiwet et al., 1990), ﬁbroblast and endothelial cell adhesion
(Bordin et al., 1990;Chen et al., 1994; Feng et al., 2002), trophoblast
FIGURE 2 |The emerging and reemerging functions of C1q.The ﬁgure is
intended not to a representative of the plethora of C1q-mediated functions,
but rather is intended to highlight the growing list of emerging and
reemerging non-traditional functions of C1q. For a more or less complete
list of C1q functions see recent paper by Nayak et al. (2010).
cell migration (Agostinis et al., 2010), regulation of dendritic cells
(Castellano et al., 2004a,b;Hosszu et al., 2010), angiogenesis (Bossi
et al., 2011), and chemotaxis of eosinophils,mast cells, neutrophils,
and dendritic cells (Ghebrehiwet et al., 1995; Kuna et al., 1996;
Leigh et al., 1998; Vegh et al., 2005). Another interesting aspect
of the C1qRs, is that both are released into the pericellular milieu,
by proliferating, activated, or proinﬂammatory cells. Because both
are capable of activating the classical pathway, it is believed that the
secreted molecules may exacerbate or trigger the local inﬂamma-
tory process. The binding site for gC1qR on C1q has been shown
to be on the A-chain of C1q (Ghebrehiwet et al., 2001), which is
the same or overlapping site to a putative IgG site (Marques et al.,
1993).
C1q DEFICIENCY AND AUTOIMMUNITY
The signiﬁcance of C1q in health and disease is further under-
scored by the fact that deﬁciency in C1q leads to a plethora of
diseases including recurrent infections, otitis media, meningitis,
pneumonia (Nishino et al., 1981; Komatsu et al., 1982) as well as
autoimmune diseases, a prototype of which is SLE. In fact, deﬁ-
ciency of C1q is considered to be a strong susceptibility factor for
SLE as evidenced by the fact that almost all (≥92%) of the known
patients with C1q deﬁciency have developed the disease (Botto
et al., 1998; Walport et al., 1998; Pickering et al., 2000). The signif-
icance of C1q in SLE is further substantiated by the ﬁnding that,
peripheral blood monocytes from SLE donors, who are not C1q
deﬁcient, have a signiﬁcantly impaired ability to upregulate C1q
synthesis both at the mRNA and protein levels, when compared
to their healthy counterparts (Moosig et al., 2006). Furthermore,
previous studies have shown SLE patients to synthesize high lev-
els of a non-functional, low molecular weight form of C1q, that
run with an apparent molecular weight of 150 kDa by gel ﬁltra-
tion (Hoekzema et al., 1985). This non-functional form of C1q
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is characterized by having an abnormal A–C disulﬁde bonding
instead of the normal pattern, which is A–B and C–C (Hoekzema
et al., 1985, 1987, 1989). Although this form of C1q retains afﬁn-
ity for the C1r2C1s2-complex, it does not bind to the Fc in IgG
aggregates (Martin and Loos, 1988). Because cultured monocytes
from normal individuals can synthesize both the dysfunctional as
well as the normal forms of C1q, it is hypothesized that in disease
states such as SLE, a condition may exist which favors a dispro-
portionate concentration of dysfunctional C1q, especially since
the normal C1q would be depleted due to complement activation
(Hoekzema et al., 1985). Although the molecular underpinnings
are still being worked out, two hypotheses have been put forth to
explain the role of C1q in SLE. The ﬁrst deals with the role of
C1q in removal of apoptotic waste. Removal of apoptotic cells and
cellular debris is essential for maintenance of tissue homeostasis,
organogenesis, remodeling, development, and maintenance of the
immune system, protection against neoplasia, and resolution of
inﬂammation. The mechanism of this removal involves the recog-
nition of the apoptotic cell surface and initiation of phagocytic
uptake bymacrophages anddendritic cells. C1q,has been shown to
play a major role both in the recognition and removal of apoptotic
cells (Casciola-Rosen et al., 1994; Korb andAhearn, 1997) through
interaction with C1q receptors expressed both on the phagocytic
cell (e.g., cC1qR/CD91; Ogden et al., 2001; Vandivier et al., 2002),
and the apoptotic cell (phosphatidylserine, DNA, and possibly
gC1qR; Païdassi et al., 2008). This in turn implies that defec-
tive clearance of immune complexes and apoptotic cells, leads to
immune recognition of hidden epitopes – a critical immunopath-
ogenic event leading to the development of SLE, the prototype
autoimmune disease. Indeed,C1q directly and speciﬁcally binds to
antigens expressed early on the surface of apoptotic cells through
its gC1q domain (Korb and Ahearn, 1997; Païdassi et al., 2008)
and the common autoantigens targeted in SLE, such as phos-
phatidylserine and DNA are found in high concentrations on the
surface of apoptotic cells (Casciola-Rosen et al., 1994). However,
while its role in removal of apoptotic debris is clearly impor-
tant, there are a number of redundant pathways involved in the
removal of self waste, thus making the role of C1q not as criti-
cal (Ghebrehiwet and Peerschke, 2004b). The second hypothesis
stipulates that autoimmunity arising from the absence or inefﬁ-
cient C1q function, especially at local sites, reﬂects an important
role in maintaining tolerance (Ghebrehiwet and Peerschke, 2004b;
Hosszu et al., 2008, 2010). Thus, while C1q could provide active
protection from autoimmunity by silencing or regulating autore-
active immune cells, its absence or defective secretion could lead to
a loss of peripheral tolerance as a sum total of impaired apoptotic
cell clearance and negative signaling (Hosszu et al., 2010). Inher-
ent in this postulate is the notion that the unique structure of C1q,
which allows it to interact with its receptors via either its cC1q or
gC1q domain,may control the transition from the monocyte state
(innate immunity) toward the professional antigen presenting cell
(APCs) state (adaptive immunity). Therefore the recent observa-
tion showing that C1q functions as a “molecular switch” during
the narrow window of monocyte to DC transition (Hosszu et al.,
2008, 2010), not only explains why C1q is primarily synthesized
by potent APCs, but also underscores why its absence can impair
antigen uptake and tolerance.
LOCAL SYNTHESIS AND FUNCTION OF C1q
As described above, most inﬂammatory cells such as those found
in atherosclerotic plaques (Peerschke et al., 2004) or cells that
undergo phenotypic differentiation or proliferation are known
to express and/or secrete C1q (Vegh et al., 2003; Bulla et al.,
2008; Hosszu et al., 2008). The emerging postulate is therefore,
that locally secreted C1q modulates cellular function (s) by an
autocrine and/or paracrine signaling mechanism. For example,
fetal trophoblast cells invading the decidua in the early stages of
pregnancy not only actively synthesize and express C1q on their
surface, but this C1q is actively involved in promoting trophoblast
invasion of the decidua (Agostinis et al., 2010). This in turn is
mediated by two cell surface receptors – gC1qR and α4β1 integrin,
which promote trophoblast adhesion and migration through the
activation of ERK1/2 MAPKs (Agostinis et al., 2010). In support
of this is the ﬁnding that C1q−/− mice manifested increased fre-
quency of fetal resorption, reduced fetal weight, and smaller litter
size when compared to their wild-type counterparts suggesting
that defective local production of C1q may be involved in preg-
nancy disorders such as preeclampsia (Agostinis et al., 2010). The
signiﬁcance of C1q in pregnancy disorders is further supported by
an independent study, which showed that pregnant C1q−/− mice
express the key features of human preeclampsia that correlate with
increased fetal death (Singh et al., 2011). Treatment of C1q−/−
mice with pravastatin restored trophoblast invasiveness, placental
blood ﬂow, and angiogenic balance and, thus, prevented the onset
of preeclampsia (Singh et al., 2011). It is also important to note
within this context, the results of recent studies, which showed
that in vivo, C1q induces angiogenesis and promotes wound heal-
ing. This in turn identiﬁes not only a novel role but also identiﬁes
C1q as a potential pro-angiogenic molecule for the treatment of
wounds and chronic ulcers (Bossi et al., 2011).
THE EMERGING ROLE OF C1q IN CARCINOGENESIS
Another emerging role of C1q is in the regulation of cancer cell
survival and progression. Recent studies have shown that C1q,
which is expressed on basal and epithelial cells of prostate tissues,
sustains the activation of the tumor suppressor WOX1 (WW-
domain containing oxydoreductase), which is needed for blocking
cancer cell proliferation. This suggests that C1q may induce apop-
tosis of prostate cancer cells by activating WOX1 and destabilizing
cell adhesion. Conversely, downregulation of C1q was found to
enhance prostate hyperplasia and cancerous formation due to fail-
ure of WOX1 activation (Hong et al., 2009). More importantly,
although C1q is expressed in the normal prostate, it is signiﬁcantly
reduced in benign prostatic hyperplasia and prostate cancer tissues
(Hong et al., 2009). Therefore, the C1q/WOX1-induced death of
cancer cells could have a universal implication in cancer, as long as
C1q and WOX1 are present in both the extracellular and intracel-
lular milieu, and are sufﬁcient in activating the apoptotic cascade
(Hong et al., 2009). However, since the autocrine or paracrine sig-
naling effect of locally expressed C1q is most likely going to be
in concert with its cell surface receptors and signaling partners, it
is important to note that both cC1qR/calreticulin (cC1qR/CRT)
and gC1qR have also been implicated in carcinogenesis, albeit
their roles seem to be rather divergent. Whereas cC1qR/CRT is
reported to have tumor suppressive effect, gC1qR appears to be
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requisite for tumor cell progression and metastasis. For exam-
ple, when Epstein–Barr virus (EBV)-immortalized B lymphocytes
were injected into nude mice, they were found to reproducibly
inhibit tumor growth (Tosato et al., 2003). This anti-tumor activ-
ity, which is released by the lymphoblastic cells, was later identiﬁed
to be a fragment of cC1qR/CRT corresponding to the N-terminal
residues 1–180. Subsequently, recombinant protein corresponding
to this N-terminal fragment was found to inhibit endothelial cell
proliferation in vitro and angiogenesis in vivo (Tosato et al., 2003).
The inhibition of endothelial cell proliferation was due to direct
binding of the cC1qR/CRT fragment to the extracellular matrix
protein, laminin thereby interfering with endothelial cell attach-
ment. Further studies showed that subcutaneous inoculation of
recombinant CRT fragment into nude mice not only prevented
the development of subcutaneous tumors, but also inhibited the
growth of established ones (Tosato et al., 2003). Since the collagen
tail of C1q (cC1q) binds to the N-terminal half of cC1qR/CRT,
which contains several short (7–10 amino acids) CH2-like motifs
(ExKxKx) similar to the C1q binding motif found in the CH2
domainof IgG (Sontheimer et al., 2003), theseC1qbinding regions
of cC1qR/CRT have the potential to be developed into therapeutic
modalities.
The receptor for the ghs of C1q, gC1qR, on the other hand,may
have functions that enhance tumor growth and tumor progres-
sion. First, histochemical staining with anti gC1qR mAb revealed
marked differential expression of gC1qR in thyroid, colon, pancre-
atic, gastric, esophageal, and lung adenocarcinomas compared to
the non-malignant histologic counterparts. In contrast, differen-
tial expressionwasnot observed in endometrial, renal, andprostate
carcinomas (Rubinstein et al., 2004; Peerschke et al., 2011). Recent
studies not only corroborated these ﬁndings, but additionally
showed that cell surface expressed gC1qR is a receptor for the
tumor homing peptide,LyP-1 (Fogal et al., 2008).Moreover, recent
studies using human lung carcinoma A549 cells have shown the
cell surface gC1qR to be a key regulator for lamellipodia forma-
tion and cancer metastasis via receptor tyrosine kinase activation.
Furthermore, the growth factor-induced lamellipodia formation
and cell migration were signiﬁcantly decreased in gC1qR-depleted
cells, with a concomitant blunt activation of the focal adhesion
kinase and the respective receptor tyrosine kinases (Kim et al.,
2001). These studies collectively suggest that gC1qR, which is
highly upregulated on the surface of tumor cells and inﬂamma-
tory cell scan serve not only as a tumor cell marker, but also
can be a target for therapeutic intervention (Peerschke et al.,
2011).
CONCLUDING REMARKS
Because of the incredible number of reports that have come out
in the past 20 years, it is not possible to list all the functions in
which C1q is involved. Therefore, while touching on some of the
well known functions of C1q, this paper underscores the role of
C1q in novel and emerging areas of diseases (e.g., preeclampsia,
cancer, and wound healing) in which either the soluble form or
the membrane associated form of C1q appear to be intimately
involved. The chimeric structure of C1q – containing two func-
tional domains – together with the fact that it is synthesized by
a wide range of proinﬂammatory cell types makes it likely that
it is a potent orchestrator of molecular pathways involved not
only in innate and adaptive immunity, but also in a wide range
of inﬂammatory diseases including cancer. The heterotrimeric
gC1q domain of C1q is also revealing itself as a powerful pat-
tern recognition domain with the ability to sense a broad range of
ligands – including a number of altered self-motifs and pathogen-
associated molecular ligands – each of which will likely trigger a
multiplicity of immunologic functions, which are either beneﬁ-
cial or deleterious to the host. More than ever, the availability of
recombinant forms of the heterotrimeric trimeric gC1q domains
will undoubtedly help us gain insight into the mechanism of inter-
action between C1q and the vast array of molecular patterns. The
best is yet to come.
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